Skip to Main Content
Services Talent Knowledge
Site Search
Menu

PressRelease

October 6, 2017

Ryan G. Ganzenmuller Joins Barclay Damon

October 6, 2017"”Barclay Damon announces Ryan G. Ganzenmuller has joined the law firm as an associate in the Torts & Products Liability Defense, Commercial Litigation, and Professional Liability Practice Areas. He is resident in the Buffalo office.

Ryan focuses his practice on litigating commercial and tort matters in federal and state courts, defending businesses, entrepreneurs, and individuals. He manages civil cases at stages that include preliminary injunctive relief, motion practice, trial, post-judgment enforcement, and appeal. Prior to joining Barclay Damon, Ryan handled business and corporate law, civil litigation, insurance coverage, intellectual property, construction law, and various commercial matters at Duke, Holzman, Photiadis & Gresens LLP.

Barclay Damon LLP, listed as a "Top 250 Firm" by The National Law Journal, is a full-service law firm with offices throughout the major cities of New York State and in Toronto, Boston, Washington DC, and Newark. At 275 lawyers, Barclay Damon is the largest law firm in the Northeastern United States that is not centered in a major market. Barclay Damon provides comprehensive legal and business counsel to a diverse client base in 33 practice areas. For more information, visit barclaydamon.com.

Subscribe

Click here to sign up for alerts, blog posts, and firm news.

Featured Media

Alerts

Massachusetts Federal Court Permits Sharing Clause in Protective Order in Products Liability Case

Alerts

NYS Court of Appeals Holds That Parent May Not Recover for Emotional Injuries in Prenatal-Injury Case

Alerts

Smarter Inventory Management for Pharmacies: Navigating Online Marketplace Compliance

Alerts

Emergency Wine Run, Now Legal: New York State Opens Retail-to-Retail Sales

Alerts

California's Updated Privacy Regulations: Automated Decisionmaking Technology, Cybersecurity Audits, and Risk Assessments, Part 1

Alerts

Pharmacies on High Alert: Optum Rx's 25-Percent Therapeutic-Class Cap Creates Major Legal, Operational, and Competitive Risks